SCHEDULE 13G/A: Rosalind Advisors and Affiliates Divest Entire Stake in Spruce Biosciences, Filing Amended 13G

Rosalind Advisors, Inc., Rosalind Master Fund L.P., and associated individuals Steven Salamon and Gil Aharon have reported a complete divestment of their beneficial ownership in Spruce Biosciences, Inc., now holding 0% of common shares.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gil Aharon have filed an Amendment No. 3 to Schedule 13G for Spruce Biosciences, Inc.
• The filing indicates that all reporting persons now beneficially own 0.00 common shares of Spruce Biosciences, Inc., representing 0.0% of the class.
• This amendment signifies a complete divestment of their previously held stake in the company.
• The event date requiring this filing was December 31, 2024, with the filing submitted on February 13, 2025.
• Rosalind Advisors, Inc. serves as the investment advisor to Rosalind Master Fund L.P., and Steven Salamon is the portfolio manager of the Advisor.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the complete divestment by a previously significant institutional investor, which typically signals a lack of confidence in the company's future prospects from the divesting party's perspective.

Negatives

• The complete divestment of beneficial ownership by Rosalind Advisors, Inc., Rosalind Master Fund L.P., and associated individuals indicates a lack of confidence or a strategic exit by these institutional investors from Spruce Biosciences, Inc.

Risks

• The divestment by a previously significant institutional holder could lead to negative investor sentiment and potential downward pressure on Spruce Biosciences, Inc.'s stock price.
• Loss of institutional support from the divesting entities may impact future capital raising efforts or market perception.

Future Outlook

The document does not contain any forward-looking statements or guidance from Spruce Biosciences, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This filing is a standard disclosure of a change in beneficial ownership by an institutional investor and does not provide broader industry context or trends for the biotechnology or pharmaceutical sector in which Spruce Biosciences operates.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential stock price decline due to the complete divestment by a significant institutional investor.

Key Dates

Recommendation

Keywords

Spruce Biosciences, Rosalind Advisors, Rosalind Master Fund, SEC filing, Schedule 13G, beneficial ownership, divestment, institutional investor, common shares, stock ownership